CA2505373A1 - Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques - Google Patents
Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques Download PDFInfo
- Publication number
- CA2505373A1 CA2505373A1 CA002505373A CA2505373A CA2505373A1 CA 2505373 A1 CA2505373 A1 CA 2505373A1 CA 002505373 A CA002505373 A CA 002505373A CA 2505373 A CA2505373 A CA 2505373A CA 2505373 A1 CA2505373 A1 CA 2505373A1
- Authority
- CA
- Canada
- Prior art keywords
- vitamin
- compounds
- administered
- compound
- active agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des procédés pour traiter des syndromes myélodysplasiques ou améliorer un symptôme de ceux-ci. Des procédés spécifiques consistent à administrer un ou plusieurs composés de vitamine D ou un sel, solvate, hydrate, stéréoisomère, clathrate ou promédicament de ceux-ci, acceptable d'un point de vue pharmaceutique, seuls ou associés à un ou plusieurs agents actifs supplémentaires. D'autres procédés consistent à administrer par intermittence une haute dose d'un ou de plusieurs composés de vitamine D ou d'un sel, solvate, hydrate, stéréoisomère, clathrate ou promédicament de ceux-ci, acceptable d'un point de vue pharmaceutique, seuls ou associés à un ou plusieurs agents actifs supplémentaires. Une telle administration par intermittence permet d'administrer de hautes doses de composés de vitamine D tout en minimisant ou supprimant l'apparition d'une hypercalcémie.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42454602P | 2002-11-06 | 2002-11-06 | |
US60/424,546 | 2002-11-06 | ||
PCT/US2003/035244 WO2004043360A2 (fr) | 2002-11-06 | 2003-11-06 | Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2505373A1 true CA2505373A1 (fr) | 2004-05-27 |
Family
ID=32312829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002505373A Abandoned CA2505373A1 (fr) | 2002-11-06 | 2003-11-06 | Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1562606A4 (fr) |
JP (1) | JP2006508125A (fr) |
KR (1) | KR20050086545A (fr) |
CN (1) | CN100386083C (fr) |
AU (1) | AU2003291294A1 (fr) |
CA (1) | CA2505373A1 (fr) |
MX (1) | MXPA05004985A (fr) |
WO (1) | WO2004043360A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
AU2004247108A1 (en) * | 2003-06-11 | 2004-12-23 | Novacea, Inc | Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents |
EP1791547A1 (fr) * | 2004-05-28 | 2007-06-06 | Abbott Laboratories | Formulations orales de paricalcitol |
US8501717B2 (en) | 2007-02-09 | 2013-08-06 | Merck, Sharp & Dohme Corp. | Methods to treat and/or prevent mucositis |
SG173119A1 (en) * | 2009-01-27 | 2011-08-29 | Berg Biosystems Llc | Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy |
CN103142478B (zh) * | 2013-03-21 | 2014-10-01 | 青岛正大海尔制药有限公司 | 骨化三醇乳剂及其制备方法 |
CN109864992B (zh) * | 2017-12-01 | 2021-07-27 | 暨南大学 | 维生素D3或其活性形式1α,25(OH)2D3在抑制PD-1表达中的应用 |
CN111228301A (zh) * | 2020-01-14 | 2020-06-05 | 哈尔滨医科大学 | 一种用于治疗血管生成介导疾病的复方制剂及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040009958A1 (en) * | 1991-01-08 | 2004-01-15 | Bone Care International, Inc. | Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2 |
JP2002509888A (ja) * | 1998-03-27 | 2002-04-02 | オレゴン ヘルス サイエンシーズ ユニバーシティー | 腫瘍および他の過増殖性疾患の治療におけるビタミンdおよびその類似体 |
AU2002363959B2 (en) * | 2001-12-03 | 2007-12-13 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
WO2004110151A1 (fr) * | 2003-06-11 | 2004-12-23 | Novacea, Inc. | Traitement du cancer au moyen de composes de vitamine d actifs associes a des agents et a des traitements radiotherapeutiques |
-
2003
- 2003-11-06 CN CNB2003801073796A patent/CN100386083C/zh not_active Expired - Fee Related
- 2003-11-06 JP JP2004551746A patent/JP2006508125A/ja not_active Withdrawn
- 2003-11-06 KR KR1020057008448A patent/KR20050086545A/ko not_active Application Discontinuation
- 2003-11-06 CA CA002505373A patent/CA2505373A1/fr not_active Abandoned
- 2003-11-06 EP EP03768685A patent/EP1562606A4/fr not_active Withdrawn
- 2003-11-06 WO PCT/US2003/035244 patent/WO2004043360A2/fr active Application Filing
- 2003-11-06 MX MXPA05004985A patent/MXPA05004985A/es not_active Application Discontinuation
- 2003-11-06 AU AU2003291294A patent/AU2003291294A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004043360A3 (fr) | 2004-10-14 |
MXPA05004985A (es) | 2005-08-02 |
CN100386083C (zh) | 2008-05-07 |
KR20050086545A (ko) | 2005-08-30 |
EP1562606A4 (fr) | 2006-05-24 |
AU2003291294A1 (en) | 2004-06-03 |
EP1562606A2 (fr) | 2005-08-17 |
WO2004043360A2 (fr) | 2004-05-27 |
JP2006508125A (ja) | 2006-03-09 |
CN1732009A (zh) | 2006-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070027120A1 (en) | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes | |
ES2211107T3 (es) | 1-alfa-hidroxi-25-eno-vitamina d, analogos y utilizaciones de los mismos. | |
US8501717B2 (en) | Methods to treat and/or prevent mucositis | |
US5795882A (en) | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations | |
AU723835B2 (en) | Method of treating prostatic diseases using active vitamin D analogues | |
JP2005510536A (ja) | 活性ビタミンd類縁物質を使用した過剰増殖性疾病の治療 | |
KR20050044655A (ko) | 활성 비타민 d 화합물을 함유하는 약제학적 조성물 | |
CA2517160A1 (fr) | Procede de traitement et de prevention de l'hyperparathyroidie par des composes vitaminiques | |
JP2010536866A (ja) | ビタミンd化合物の用量範囲を拡張する方法 | |
AU2010261967B2 (en) | New therapeutical uses of inecalcitol | |
CA2505373A1 (fr) | Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques | |
UA110211C2 (uk) | Нові склади 14-eпi-аналогів вітаміну d | |
MXPA00011215A (en) | 1&agr;-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF | |
WO2012128653A1 (fr) | Utilisation d'anastrozole et d'analogue de vitamine d dans polythérapie contre le cancer du sein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20101108 |